Jay Parrish is Chief Business Officer at Vir Biotechnology, Inc. (VIR). They have made 12 open-market trades across 1 company since 2020, most recently 2021-04-01.
CIK 0001786372
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 12 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| VIR | 9,260 | $92K |
Shares reported on the most recent Form 4, priced at the 2021-04-05 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VIR | SELL | 2021-04-01 | 2021-04-05 | $51.40 | $714K | -5.6% | -9.0% | -13.4% |
| VIR | SELL | 2021-03-01 | 2021-03-03 | $63.44 | $881K | +31.6% | +22.7% | +5.1% |
| VIR | SELL | 2021-02-01 | 2021-02-02 | $69.91 | $971K | +16.2% | -33.9% | -22.8% |
| VIR | SELL | 2021-01-04 | 2021-01-05 | $26.32 | $366K | +50.1% | +147.2% | +85.5% |
| VIR | SELL | 2020-12-01 | 2020-12-02 | $31.53 | $438K | +7.7% | -11.7% | +90.6% |
| VIR | SELL | 2020-11-02 | 2020-11-03 | $31.27 | $434K | -15.7% | -1.6% | +107.7% |
| VIR | SELL | 2020-10-01 | 2020-10-02 | $34.75 | $483K | +17.4% | -12.1% | -23.5% |
| VIR | SELL | 2020-09-01 | 2020-09-03 | $39.15 | $544K | +9.1% | +29.5% | +2.5% |
| VIR | SELL | 2020-08-03 | 2020-08-04 | $47.65 | $1.1M | +3.4% | -39.2% | -39.7% |
| VIR | SELL | 2020-07-01 | 2020-07-02 | $37.95 | $2.8M | +30.6% | +27.6% | -11.5% |
| VIR | SELL | 2020-06-01 | 2020-06-02 | $35.22 | $2.6M | -6.7% | +10.0% | +10.4% |
| VIR | SELL | 2020-05-14 | 2020-05-15 | $30.05 | $2.3M | -5.7% | +6.5% | +57.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.